Single Centre, Prospective, Open, Non Controlled, Pilot Study for Efficacy and Security Evaluation of Low Nephrotoxicity Immunosuppression, Based on the Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Renal function improvement after liver transplant
Creatinine (mg/dL) and MDRD Glomerular Filtrate Rate (ml/min/1.73m2) will be measured following the time frame described above
Measurement will be performed at 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 14th and 28th day post-transplant, and 2nd, 3rd, 6th and 12th month post-transplant
Yes
ITXARONE BILBAO, PhD/MD
Principal Investigator
Department of HPB Surgery and Transplants, Hospital Vall d´Hebron (Barcelona, Spain)
Spain: Comité Ético de Investigación Clínica
ATG-IRA-HVH.10
NCT01453218
October 2011
Name | Location |
---|